Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Down 24.9% in March

Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 113,900 shares, a decline of 24.9% from the March 15th total of 151,700 shares. Currently, 0.8% of the company's shares are sold short. Based on an average daily volume of 127,100 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Investors Weigh In On Ikena Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of IKNA. Squarepoint Ops LLC bought a new position in shares of Ikena Oncology during the 4th quarter worth $72,000. BNP Paribas Financial Markets purchased a new stake in Ikena Oncology in the fourth quarter worth about $72,000. Northern Trust Corp grew its holdings in Ikena Oncology by 19.7% during the 4th quarter. Northern Trust Corp now owns 57,565 shares of the company's stock worth $94,000 after acquiring an additional 9,456 shares in the last quarter. Gilead Sciences Inc. purchased a new position in Ikena Oncology during the 4th quarter valued at about $3,294,000. Finally, Geode Capital Management LLC raised its holdings in shares of Ikena Oncology by 21.0% in the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock valued at $538,000 after purchasing an additional 56,936 shares in the last quarter. 75.00% of the stock is owned by institutional investors.

Ikena Oncology Stock Performance

Shares of NASDAQ IKNA remained flat at $1.21 during mid-day trading on Thursday. 60,213 shares of the stock were exchanged, compared to its average volume of 172,674. The firm has a market cap of $58.39 million, a PE ratio of -0.98 and a beta of 0.48. Ikena Oncology has a 12-month low of $0.97 and a 12-month high of $1.94. The stock's 50 day moving average price is $1.28 and its 200-day moving average price is $1.51.

Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. As a group, sell-side analysts predict that Ikena Oncology will post -0.91 earnings per share for the current year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.